ArticleFrontiers of medicine2025
Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma.
Article in Frontiers of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We hypothesized that gene networks converged between plasma cell development and multiple myeloma (MM) pathogenesis may better explain the clinical heterogeneity in individual MM patients. Here, we transformed the reciprocal expression pattern between a gene module centered on the expression of MCL1 and another gene module represented by the expression of TLR10 from individual MM transcriptomes into a myeloma classification score (MCS). MCS enabled prognostication in 1738 patients with newly diagnosed MM (NDMM) and 319 patients with relapsed/refractory MM (RRMM) from our own observational cohort, from MMRF, and from five prospective trials. MCS also enabled the discrimination between progressive and stable disease states in the longitudinal samples from 85 patients in MMRF and the PETHEMA/GEM2012MENOS65 trial. MCS further enabled prediction of the responses to bortezomib-based treatment in 425 patients enrolled in the HOVON-65/GMMG-HD4 and APEX (039) trials, and the response to carfilzomib-based treatment in 86 transplantation-eligible patients from MMRF. MCS-defined risk groups harbored distinct targetable pathways, including unfolded protein response, replication stress, genomic instability and interferon responses. However, MCS-based individualized prediction of prognosis and treatment response was independent of the hitherto available prognostic models. Thus, MCS represents an alternative biomarker for risk stratification and prediction of treatment response in individual MM patients.
Indexed as
Identifiers
41405832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.